Biosimilar Market by Product (Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory Agents, and Others), Application (Oncology Diseases, Blood Disorders, Chronic & Autoimmune Diseases, Growth Hormone Deficiencies, and Others), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021–2028

Global Biosimilar Market Analysis

The global biosimilar market size is predicted to garner $83,836.40 million in the 2021–2028 timeframe, growing from $14,477.30 million in 2020, at a healthy CAGR of 24.90%.

Market Synopsis

Strategic alliances among market players, along with growing demands for biosimilar across the globe, are expected to accelerate the growth of the biosimilar market.

However, complexities in manufacturing biosimilar are some of the growth-restricting factors for the market.

According to the regional analysis, the Asia-Pacific biosimilar market size is anticipated to grow during the review period and generate a revenue of $21,965.10 million, with CAGR of 25.50% due to increasing demand for biosimilar in the region.

Biosimilar Overview

Biosimilar is a medicine that has almost same function and structure of the biologic drugs manufactured by different companies. Biosimilars are licensed by the US Food and Drug Administration (FDA). The main aim of biosimilars is to reduce the cost of healthcare system and to grow access to treatment in the forthcoming years as costly biological drugs lose patent protection.

Covid-19 Impact on Biosimilar Market Shares

The novel coronavirus pandemic severely affected several industries. The global biosimilar market experienced negative growth during this period. Disruption in manufacturing capacity and supply chain during the COVID-19 period is one of the factors that might have affected the market for biosimilar. Furthermore, the negative growth of the market is owing to challenges faced by pharma companies in development of biosimilar. Also, FDA approvals are reduced for non-COVID therapeutics due to pandemic which is expected to delay the process of drug approvals or launches, thereby hindering the market growth. All such factors are expected to negatively affect the biosimilar industry.

Increasing Demand of Biosimilar Drugs due to Their Cost-effectiveness to Surge the Market Growth

The global biosimilar industry is witnessing a massive growth mainly due to increasing demand for biosimilar drugs due to their cost-effectiveness. According to American Journal of Managed Care, biosimilars are cost effective and have 20–30% lower prices than their parent counterparts. Moreover, biosimilars have low R&D costs; all such factors may fuel the growth of the global biosimilar market.

Furthermore, biosimilar industry is booming because government is highly supporting in the development and approval of biosimilars. For instance, US Food and Drug Administration (FDA), in July 2021, revealed that they have approved the biosimilar insulin product for type-1 and type-2 diabetes, and this will offer patients cost effective, safe, and high quality options for treating diabetes. These types of factors are predicted to drive the growth of the market.

To know more about global biosimilar market trends, drivers, get in touch with our analysts here.

High Cost of Biosimilar to Restrain the Market Growth

Biosimilar is highly complex and costly in terms of manufacturing and production. Also, biosimilar requires technical capabilities, significant investments, scientific standards, clinical trial expertise, and quality systems. These are some of the factors anticipated to hinder the market value of the biosimilar in the next few years.

Patent Expiry of Biologics and Research on New Biosimilars to Create Massive Investment Opportunities

The global biosimilar market is spreading at a very fast pace due to increasing demand for new biosimilars as in the 20^th century most of the biologic drugs lost the patent protection. Moreover, most of the best selling drugs are going to be expired in upcoming years and this will bring new opportunities in the biosimilar industry. All such factors are positively affecting the biosimilar market growth.

Furthermore, biosimilar industry already has leading market players innovating strategies to attract customers. For example, in 2019, Amgen, American multinational biopharmaceutical company and Allergan, American global pharmaceutical company launched two biosimilars for cancer treatment in US market. All such types of product launch, innovations, and strategic alliances will accelerate the overall functional beverage market and it will bring lucrative market opportunities for key players in the upcoming years.

To know more about global biosimilar market trends, opportunities, get in touch with our analysts here.

Source: Research Dive Analysis

The monoclonal antibodies type sub-segment is predicted to have a dominating share as well as fastest market growth in the global market and register a revenue of $29,987.30 million during the forecast period. Monoclonal antibodies have large applications in autoimmune disorders, treatment of cancer, osteoporosis, and rising incidents of insulin dependent diabetes globally. These factors and strategic alliances may bolster the growth of the sub-segment during the forecast period and increase biosimilar market demand.

Source: Research Dive Analysis

The oncology diseases sub-segment of the global biosimilar market growth is projected to be the dominant as well as have the fastest growth and surpass $29,241.40 million by 2028, with an increase from $4,933.80 million in 2020. This growth in the market can be attributed to growing number of cancer patients and availability of biosimilars at low costs. These elements may increase the demand for sub-segment and biosimilar market demand.      

Source: Research Dive Analysis

The Market for Biosimilar in Europe to be the Most Dominant

The Europe biosimilar market accounted $5,863.30 million in 2020 and is projected to register a revenue of $34,121.40 million by 2028. The extensive growth of the Europe biosimilar market is mainly driven by factors such as rising incidence of chronic disorders, implementing the patent expiry of biologic products, the emergence of new players, and the launch of new biosimilars. These are some of the factors that are fueling the market growth across the globe. These factors will ultimately drive the demand for the biosimilar market across the region.

The Market for Biosimilar in Asia-Pacific to be the Fastest Growing

The share of Asia-Pacific biosimilar market is expected to rise at a CAGR of 25.50%, by registering a revenue of $21,965.10 million by 2028. The growth shall be a result of presence of pharmaceutical companies and large R&D investment in development of biosimilars.

Competitive Scenario in the Global Biosimilar Market

Product launches and mergers & acquisitions are common strategies followed by major market players.

Source: Research Dive Analysis

Some of the leading biosimilar market players are Merck Serono (Merck Group), Teva Pharmaceutical Industries Ltd., Novartis (Sandoz), Synthon Pharmaceuticals, Inc., LG Life Sciences, Celltrion, Biocon, Hospira, Genentech (Roche Group), and Biogen idec, Inc.

Porter’s Five Forces Analysis for the Global Biosimilar Market:

• Bargaining Power of Suppliers: The product suppliers of biosimilar market are high in number and are larger and more globalized. Bargaining power of supplier depends upon production process and raw material requirement. So, there will be less threat from the suppliers.
  Thus, the bargaining power of suppliers is low. 
• Bargaining Power of Buyers: Buyers have huge options to select from different biosimilars; this has increased the pressure on the biosimilar providers to offer the best product. This gives the buyers the option to freely choose biosimilar products that best fit their preference.
  Thus, the bargaining power of the buyers is high. 
• Threat of New Entrants: Companies entering the biosimilar market are adopting various innovations, but difficulty and time required for FDA approval for drugs are some of the factors that can strict the entry of new drug in the biosimilar market.
  Thus, the threat of the new entrants is low.
• Threat of Substitutes: There is no substitute available for biosimilars; Whenever customer demand is satisfied with any of the services or products, they will adopt such product and services.
  Therefore, threat of substitutes is low. 
• Competitive Rivalry in the Market: The competitive rivalry among industry leaders is rather intense, especially between the global players including Novartis (Sandoz) and Synthon Pharmaceuticals, Inc. These companies are launching their value-added services in the international market and strengthening the footprint worldwide.
  Therefore, competitive rivalry in the market is high.